Predictors of Crohn's disease

被引:701
作者
Beaugerie, L
Seksik, P
Nion-Larmurier, I
Gendre, JP
Cosnes, J
机构
[1] Hop St Antoine, Serv Gastroenterol, Dept Gastroenterol, F-75571 Paris 12, France
[2] Univ Paris 06, Paris, France
关键词
D O I
10.1053/j.gastro.2005.12.019
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Early intensive therapy in Crohn's disease should be considered only in patients with disabling disease. The aim of our study was to identify at diagnosis factors predictive of a subsequent 5-year disabling course. Methods: Among the 1526 patients seen at our unit with Crohn's disease diagnosed between :1985 and 1998, we excluded patients operated on within the first month of the disease, patients with inadequate data, and patients with severe chronic nondigestive disease. In the 1188 remaining patients, Crohn's disease course within the first 5 years of the disease was categorized as disabling when at least 1 of the criteria of clinical severity, conventionally predefined, was present. Results: Among the 1123 patients with follow-up data allowing full 5-year course classification, the rate of disabling disease was 85.2%. Independent factors present at diagnosis and significantly associated with subsequent 5-year disabling were the initial requirement for steroid use (OR 3.1 [95% Cl: 2.2-4.4]), an age below 40 years (OR 2.1 [95% Cl: 1.3-3.6]), and the presence of perianal disease (OR 1.8 [95% Cl: 1.2-2.8]). The positive predictive value of disabling disease in patients with 2 and 3 predictive factors of disabling disease was 0.91 and 0.93, respectively. These values were 0.84 and 0.91, respectively, when tested prospectively in an independent group of 302 consecutive patients seen at our institution from 1998. Conclusions: At diagnosis of Crohn's disease in a referral center, factors predictive of subsequent 5-year disabling course are an age below 40 years, the presence of perianal disease, and the initial requirement for steroids.
引用
收藏
页码:650 / 656
页数:7
相关论文
共 28 条
[1]  
BEAUGERIE L, 1989, GASTROEN CLIN BIOL, V13, P1036
[2]   Guidelines for the management of inflammatory bowel disease in adults [J].
Carter, MJ ;
Lobo, AJ ;
Travis, SPL .
GUT, 2004, 53 :v1-v16
[3]   The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients [J].
Colombel, JF ;
Loftus, EV ;
Tremaine, WJ ;
Egan, LJ ;
Harmsen, WS ;
Schleck, CD ;
Zinsmeister, AR ;
Sandborn, WJ .
GASTROENTEROLOGY, 2004, 126 (01) :19-31
[4]   Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery [J].
Cosnes, J ;
Nion-Larmurier, I ;
Beaugerie, L ;
Afchain, P ;
Tiret, E ;
Gendre, JP .
GUT, 2005, 54 (02) :237-241
[5]   Do immunosuppressants have any impart on the need for surgery in Crohn's disease ? [J].
Cosnes, J ;
Larmurier, IN ;
Beaugerie, L ;
Gendre, JP .
GASTROENTEROLOGY, 2003, 124 (04) :A10-A10
[6]   Smoking cessation and the course of Crohn's disease: An intervention study [J].
Cosnes, J ;
Beaugerie, L ;
Carbonnel, F ;
Gendre, JP .
GASTROENTEROLOGY, 2001, 120 (05) :1093-1099
[7]   Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine [J].
Dayharsh, GA ;
Loftus, EV ;
Sandborn, WJ ;
Tremaine, WJ ;
Zinsmeister, AR ;
Witzig, TE ;
Macon, WR ;
Burgart, LJ .
GASTROENTEROLOGY, 2002, 122 (01) :72-77
[8]   Maintenance therapy for inflammatory bowel disease [J].
Feagan, BG .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (12) :S6-S17
[9]   A simple classification of Crohn's disease: Report of the Working Party for the world congresses of gastroenterology, Vienna 1998 [J].
Gasche, C ;
Scholmerich, J ;
Brynskov, J ;
D'Haens, G ;
Hanauer, SB ;
Irvine, EJ ;
Jewell, DP ;
Rachmilewitz, D ;
Sachar, DB ;
Sandborn, WJ ;
Sutherland, LR .
INFLAMMATORY BOWEL DISEASES, 2000, 6 (01) :8-15
[10]   Crohn's disease: step up or top down therapy [J].
Hanauer, SB .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2003, 17 (01) :131-137